Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

LUNGevity Foundation

Status: Enrolling

Conditions: Lung Cancer Patients; Caregivers

Treatments: Other: There are no interventions in this study. All participants complete online surveys.

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05826756

LUNGevity-2020-01

Details and patient eligibility

About

LUNGevity Foundation, a non-profit lung cancer organization, wants to learn about living with lung cancer from the point of view of people with lung cancer and their family and friends who provide care. To do this, we have an online study designed to better understand how treatments people living with lung cancer receive impact their quality of life. Participants will complete surveys once a month for 12 months.

What does participation involve?

1. Emailing the study team to learn more and get access to the study website.
2. Once a month for 12 months you will receive a survey by email.
3. Complete these surveys on a smartphone, tablet, or computer at your convenience and receive an e-gift card for your time.

Full description

PEER is an international study, that is Institutional Review Board (IRB) approved and General Data Protection Regulation (GDPR) compliant.

The study objective is to collect longitudinal data to facilitate a rigorous understanding of the diagnostic and treatment experiences of people diagnosed with lung cancer and to identify determinants of treatment heterogeneity. Study data will be used to understand the diagnostic and treatment pathways, explore patient-experience data in different domains (financial impact/quality of life/symptoms) and test the hypothesis that different classes of therapies (chemotherapy/ immunotherapy/ targeted therapy/ surgery/ radiation) impact patient experience (eg., physical function).

Study participants will consent and register for the study and complete an initial baseline survey. They will then be followed for 12 months and receive a monthly survey (11 surveys in total) via email. The development of the surveys was guided by input from patients, clinicians, FDA experts, and incorporates questions from existing patient-reported outcomes (PRO) measures.

Summarized study results will also be posted on LUNGevity's website. External researchers will be able to apply to have limited access to de-identified data.

Enrollment: 1,300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with self-reported lung cancer diagnosis or caregiver of someone with a self-reported lung cancer diagnosis (patient has to be alive)
• Ability to read and answer questions in English
• Access and ability to use a computer or other internet-connected device

Exclusion criteria

• Younger than 18
• Healthcare providers and healthcare professionals who provide care to lung cancer patients except for those who are themselves a patient or a caregiver to a loved one.
• Not able to provide informed consent

Trial design

1,300 participants in 2 patient groups

Patients

Description:

Individuals who have been diagnosed with lung cancer. Individuals with all stages of lung cancer and individuals who have reached no evidence of disease (NED).

Treatment:

Other: There are no interventions in this study. All participants complete online surveys.

Caregivers

Description:

Family and friends who provide care for someone who has been diagnosed with lung cancer

Treatment:

Other: There are no interventions in this study. All participants complete online surveys.